Czechia· CZ-0203396
CARAMLO
A candesartan und amlodipin product containing amlodipine besilate + candesartan cilexetil, registered in Czechia by Zentiva, k.s., Praha. The same ATC class is registered in 6 of our 19 countries.
Checked against SÚKL (Czech Republic) on
Informational only — not a medical device.
Where it is registered
Candesartan und amlodipin is registered in 6 of 19 countries.
Countries holding a registration under ATC C09DB07 (candesartan und amlodipin), each read from that country’s own register.
- This record: Czechia, from SÚKL (Czech Republic)
- 6 of them publish a price we can compare per daily dose
Candesartan und amlodipin · ATC C09DB07
6 / 19 countries
- Belgiumprice
- Czechiaprice
- Finlandprice
- Italyprice
- Polandprice
- Switzerlandprice
The record
At a glance
SÚKL (Czech Republic)- Active substance
- AMLODIPINE BESILATE + CANDESARTAN CILEXETIL
- Manufacturer
- Zentiva, k.s., Praha
- Country
- Czechia (CZ)
- ATC code
- C09DB07
- ATC class
- Candesartan und Amlodipin
- Reimbursed
- Not published by this register
- Source register
- SÚKL (Czech Republic)
- Last checked
- September 28, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
8 interactions on record for candesartan und amlodipin.
Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Candesartan und amlodipin · interactions on record
8 records
8 more interactions with mechanism and management, from a commercially licensed source.
Sign in to checkSame medicine, other countries
Candesartan und amlodipin in 3 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- ItalyCANDESARTAN E AMLODIPINA DOCDOC GENERICI S.R.L.
- GermanyCamlostarAristo Pharma Gmbh (Art 57)
- FinlandAltensilLusomedicamenta Sociedade Técnica Farmacêutica SA
Authorised across Europe · EMA
The same active substance is authorised in 19 EEA countries. Names it is sold under:
- Austria · Candam, Candeblo Amlo
- Belgium · Candesartan/Amlodipine Krka
- Bulgaria · Bilamcar 16 Mg/10, Bilamcar 8 Mg/10 Mg
- Germany · Camlostar, Candeamlo
- Estonia · Camdero, Zenicamo
- Spain · Kandoset
- Finland · Candecam
- France · Ikpara
- United Kingdom (Northern Ireland) · Candesartan Cilexetil/Amlodipine Zentiva
- Greece · Bilamcar, Caramlo
- Hungary · Kandoset
- Italy · Candesartan E Amlodipina, Candesartan E Amlodipina Doc
- Latvia · Camlocor, Zenicamo
- Malta · Clodipan
- Poland · Camlocor, Candezek Combi
- Portugal · Altensil, Amlodipina + Candesartan Krka
- Romania · Caramlo, Kandoset
- Slovenia · Amcandin, Camlocor
- Slovakia · Bilamcar 16 Mg/10 Mg, Bilamcar 16 Mg/5 Mg
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/afa6a5cc-0e08-4e29-a1f3-e08864449cfb GET /v1/drugs/afa6a5cc-0e08-4e29-a1f3-e08864449cfb?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "TBL NOB",
"source": "sukl",
"strength": "8MG/5MG",
"pack_size": "56",
"substance": "AMLODIPINE BESILATE + CANDESARTAN CILEXETIL",
"cz_kod_sukl": "0203396",
"product_type": "CH",
"substance_codes": "12990,15205",
"registration_state": "R",
"registration_number": "58/246/14-C"
}See everything about candesartan und amlodipin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.